

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/35014> holds various files of this Leiden University dissertation.

Author: Luppino, Floriana Samantha

Title: Metabolic disturbances in depression : epidemiological studies on the role of diagnostic approach and treatment setting

Issue Date: 2015-09-03

Chapter 4

Symptom dimensions of depression and anxiety and the metabolic syndrome



Authors: Floriana S. Luppino, M.D.; Arianne K.B. van Reedt Dortland, MSc; Klaas J. Wardenaar, MSc; Paul F. Bouvy, M.D. PhD; Erik J. Giltay, M.D. PhD; Frans G. Zitman, M.D. PhD; Brenda W.J.H. Penninx PhD.

Published: Psychosomatic Medicine, 2011.

Abstract

Objective: To investigate the association between depression and anxiety symptoms and the MetSyn using a dimensional approach. The association between depression and anxiety on the one hand and the metabolic syndrome (MetSyn) as a cluster or its individual components on the other hand is equivocal. The categorical nature of the *DSM-IV* might partly explain the inconsistent findings.

Methods: In 2433 Netherlands Study of Depression and Anxiety (NESDA) study participants (mean age = 42.3 years, 33.1% male), three symptom dimensions -lack of positive affect (PA, depression specific), negative affect (NA, a-specific) and somatic arousal (SA, anxiety specific) - were assessed by a shortened adaptation of the Mood and Anxiety Symptom Questionnaire (MASQ-D30). The association between symptom dimensions and MetSyn components (waist circumference, triglycerides, high density lipoprotein (HDL) cholesterol, glucose and mean blood pressure) was analyzed using linear regression analysis.

Results: The prevalence rate of the MetSyn was 20.1% ($n = 490$). SA, but not PA and NA, was strongly associated with four out of five MetSyn components, especially waist circumference, triglycerides and blood pressure ($\beta = .046$; $P = .01$, $\beta = .077$; $P < .001$ and $\beta = .069$; $P < .001$, respectively), and with the total number of MetSyn components ($\beta = .098$; $P < .001$).

Conclusions: Our results demonstrate a strong association of most of the MetSyn components with the somatic arousal dimension, but not with the a-specific and depression-specific affect scales.

Introduction

Mood and anxiety disorders are related to an increased risk of cardiovascular morbidity and mortality.^{1,2} The metabolic syndrome (MetSyn) is a cluster of cardiovascular risk factors (i.e., elevated waist circumference, triglycerides, blood pressure and fasting glucose, and reduced high density lipoprotein (HDL) cholesterol)³ and is thought to partly mediate this relationship.⁴ The association between depression and anxiety and the MetSyn has been extensively investigated. Most studies focused on the association between depression and the cluster of the MetSyn and its individual components.^{1,5} Other studies, however less numerous, investigated the association between anxiety and both the MetSyn cluster and its individual components.^{6,7} In addition, in a recent publication,⁸ we examined whether disorder status and symptom severity were associated with the metabolic syndrome (MetSyn). No significant difference was found between subjects with and without psychopathology (both depression and/or anxiety). Only the subgroups of the most severely depressed or anxious subjects had increased prevalence rates of the MetSyn, an association predominantly driven by abdominal obesity and dyslipidaemia. Despite the observations described above, the question remains whether a complete mood disorder diagnosis or rather only specific symptom dimensions are related to the MetSyn and, whether the dichotomous MetSyn diagnosis or only some of its components are related to psychopathology dimensions.

There are three major reasons that could explain why this question has so far remained unanswered. First, the studies so far have been conducted in widely differing samples which limits the possibilities to formulate a broadly generalizable model. For instance, there have been differences in the settings (e.g., clinical population or the general population)⁹ age of the subjects (an elderly population¹⁰ or young adult patients¹¹), and the assessment of psychopathology (questionnaires¹² versus clinical diagnoses¹³). Second, the categorical diagnostic *DSM-IV* approach for depressive and anxiety disorders, lumping together disparate symptom clusters, may have limited the power to detect subtle associations.¹⁴ In fact, patients with the same diagnosis can be very different in terms of their symptom profiles, while other individuals with important mental health problems fail to meet the diagnostic criteria due to symptom heterogeneity. Third, like the *DSM-IV* diagnosis, the MetSyn concept is also heterogeneous, and is in fact subject of substantial debate.^{15,16} Since at least three components, out of five, are needed to fulfill the criteria of the MetSyn, there are numerous combinations of components possible that all lead to the same MetSyn diagnosis. In fact, studies have shown that sometimes only specific components of the MetSyn are associated with depression,¹⁷ which casts doubt over the usability of the total MetSyn concept in psychopathology research. It is possible that, in the large variety of depression/anxiety symptoms, some are 'specifically' associated with a distinct MetSyn component (e.g., energy loss, often leading to decreased physical activity, might lead to elevated waist circumference). Based on the criticized definition of the MetSyn, and the possible specific

associations between diagnostic and MetSyn symptoms, it would thus be informative to investigate the association between specific depression/anxiety symptoms on the one hand, and the MetSyn, both defined as a cluster of symptoms, and as individual components, on the other hand.

So far, research on the association between depression and anxiety and the MetSyn has mainly focused on categorical and heterogeneous assessments of affective disorders symptomatology or anxiety and depression severity scales.^{18;19} In addition, diagnoses show overlapping criteria and comorbidity rates are high.^{20;21} To overcome these problems, diagnoses should be more homogeneous and not dichotomous. A feasible alternative for categorical diagnoses is the use of a dimensional approach. Within a dimensional approach, a patient is described in terms of coexisting different symptom domains or dimensions, and not in terms of presence or absence of psychopathology. Each dimension provides specific information on the level of a specific symptom domain, running from absent or healthy to severe. Importantly, dimensions are continuous by principle. Along a continuous scale, changes from one level to another are subtle, while in a dichotomous scale, changes are rough and restricted (e.g., depressed versus non-depressed). This makes continuous variables more sensible for detection of (small) differentiating factors,²² thus increasing statistical power.²³

A well-known dimensional model is the tripartite model for depression and anxiety²⁴ which distinguishes three symptom dimensions. The broad 'negative affect' (NA) dimension describes general symptoms of psychological distress (e.g. lack of concentration or pessimism) that are seen both in depression and anxiety and could account for their high comorbidity. The (lack of) 'positive affect' (PA) dimension (also called anhedonic depression), covers anhedonic symptoms, which are mainly specific to depression. The 'somatic arousal' (SA) dimension covers symptoms of hyperarousal (e.g. palpitations, shortness of breath and dizziness), which are specific for anxiety, especially panic disorder. The dimensional model was not developed for detection of *DSM-IV* diagnoses, but rather to provide a descriptive alternative for the presence or absence of psychopathological symptoms in a subject. The tripartite model was in fact developed to circumvent the lack of diagnostic specificity due to the high levels of comorbidity observed in depression and anxiety, one of the major problems of the *DSM-IV* "golden standard". Typifying patients in terms of their NA, PA and SA scores, has two advantages: first, comorbidity is circumvented and second, based on the profile of the scores, patients can be described in more specific terms of symptomatology. Several studies have shown these specific dimensions to be specifically increased in depression (PA) and anxiety (mainly panic disorder, SA) and that NA was more indicative for overall severity across patients.^{25;26}

The aim of the present study was to investigate the relationship between the symptom dimensions of depression and anxiety of the tripartite model, and the MetSyn and its individual components within the NESDA study, as a dimensional approach makes it possible to more specifically look into these associations.

Methods and materials

Subjects

Subjects selected for these analyses were baseline participants of NESDA, a cohort study among 2981 individuals aged 18 through 65 years. Respondents were recruited in the community, in primary care, and in specialized mental health care from September 2004 through February 2007, throughout the Netherlands. All subjects completed a medical exam, a face-to-face interview, and self-report questionnaires. A detailed description of NESDA is reported elsewhere.^{25;27} The study protocol was approved by the Ethical Review Board of each participating center and all subjects signed an informed consent.

In the same study sample, tricyclic antidepressant (TCA) users were found to have a significantly increased prevalence of the MetSyn.⁸ This association was not found for users of other types of antidepressants, such as selective serotonin reuptake inhibitors (SSRI's).⁸ Therefore the relatively small group of TCA users (n=80) was excluded from our analyses, so that the results would not be affected by the potential confounding influence of tricyclic antidepressants.

Subjects with missing MetSyn or MASQ values (n=468) were excluded as well, resulting in a sample of 2433 subjects (81.6%). An important number of the included subjects were healthy controls or remitted patients (n=1449), while other subjects had a current diagnosis of pure depression (n=222), pure anxiety (n=226), or comorbid disorder (n=536). No inpatients were included. The included subjects did not differ from the excluded group in sex distribution, presence of cardiovascular disease (CVD) and physical activity. Included subjects were older (42.3 years versus 40.0 years, $P < .001$), were more educated (12.3 versus 11.3 years, $P < .001$), were less often smokers (35.8% current smokers versus 50.9%, $P < .001$) and consumed more alcohol (16.4% consumed > 2 glasses/day versus 15.3%, $P < .001$) compared to the excluded subjects.

Measurements

MASQ dimensions

The three dimensions of the tripartite model were measured with the 30-item adaptation (MASQ-D30) of the Mood and Anxiety Symptom Questionnaire (MASQ).^{26;28} The MASQ-D30 was previously validated and showed reliability and validity within the NESDA study.^{25;29;30} The MASQ-D30 consists of three 10-item scales, representing NA, PA and SA (Table 1). On each item participants were asked to rate how much in the past week they have experienced “feelings, sensations, problems and experiences that people sometimes have” on a 5-point scale, 1 being “not at all” and 5 being “extremely”. Higher scores indicate more severe symptom levels for that specific dimension.

Negative Affect	Positive Affect	Somatic Arousal
Felt confused	Felt successful	Startled easily
Felt worthless	Felt really happy	Felt nauseous
Felt irritable	Felt optimistic	Felt dizzy or light-headed
Felt hopeless	Felt like I was having a lot of fun	Was trembling or shaking
Blamed myself for a lot of things	Felt like I accomplished a lot	Had pain in my chest
Felt dissatisfied with everything	Felt like I had a lot to look forward to	Had hot or cold spells
Felt pessimistic about the future	Felt really talkative	Was short of breath
Felt inferior to others	Felt really "up" or lively	Muscles were tense or sore
Had trouble making decisions	Felt like I had a lot of energy	Heart was racing or pounding
Worried about a lot of things	Felt really good about myself	Had trouble swallowing

Table 1. Individual symptoms incorporated in the three dimensions of the MASQ-D30.

The metabolic syndrome

The MetSyn and its components, when expressed as dichotomous variables (i.e., elevated WC, triglycerides, blood pressure and fasting glucose, and reduced HDL-cholesterol) were exactly defined according to the revised criteria of the National Cholesterol Education Program – Adult Treatment Panel III (NCEP-ATP III).³ WC was measured with a measuring tape at the central point between the lowest rib and the highest point of the iliac crest, upon light clothing. Triglycerides, HDL-cholesterol, and glucose levels were determined by standardised routine laboratory assays, and diastolic and systolic blood pressure were measured during supine rest by an OMRON M4 IntelliSense Digital Blood Pressure Monitor, HEM-752A (Omron Healthcare, Inc., Bannockburn, Illinois). Use of triglyceride or HDL-cholesterol influencing medication, and use of antihypertensive or glucose reducing drug was registered. In addition we used continuous variables for the MetSyn components (which is preferable when aiming for more statistical power²³). In these analyses we ‘adjusted’ the values for those subjects using a MetSyn component influencing medication. This was done following the methods described in several previous publications.^{31;32} For the use of fibrates, 0.10 mmol/l [3.8 mg/dl] was subtracted from HDL-cholesterol, and 0.67 mmol/l [60 mg/dl] was added to triglycerides. For the use of nicotid acid, 0.15 mmol/l [5.8 mg/dl] was subtracted from HDL-cholesterol, and 0.19 mmol/l [17 mg/dl] was added to triglycerides. For the use anti-diabetic medication and a glucose level below 7.0 mmol/l [126 mg/dl], a value of 7 mmol/l [126 mg/dl] was given to glucose, as was done previously.³³ Mean blood pressure (MBP) was expressed as the arithmetic mean of systolic and diastolic blood pressures, which were both measured twice during supine rest on the right arm by an OMRON M4 IntelliSense Digital Blood Pressure Monitor, HEM-752A (Omron Healthcare, Inc., Bannockburn, Illinois) and averaged over the two measurements. For persons using antihypertensive medication, 10 mmHg was added to

systolic blood pressure, and 5 mmHg to diastolic blood pressure, in line with earlier studies.³³ These values represent the average decline in blood pressure in antihypertensive medication trials.^{34;35}

Severity scales

Information on depression and anxiety severity was collected during the baseline measurement of the NESDA study²⁷ using the Beck Anxiety Inventory (BAI),³⁶ and the Inventory of Depressive Symptoms self-report (IDS-SR),³⁷ in which the most severe groups were defined as 'severe anxiety symptoms' with a score of ≥ 29 on the BAI and 'very severe depressive symptoms' with a score of ≥ 49 on the IDS-SR. Previous NESDA research⁸ indicated that the prevalence rates of the MetSyn were increased in those with severe anxiety symptoms (n=185) in crude models and independently increased in those with very severe depressive symptoms (n=102) after fully adjusted models. Since information on the BAI and IDS-SR scores was available for our sample, we decided to investigate whether the previous found associations in the same cohort between the highest scores of the BAI and IDS severity scales and metabolic derangements would be driven by symptom dimensions.

Covariates

Covariates were grouped into two types of variables: sociodemographic and lifestyle variables. Sociodemographic variables included age, sex and years of education. Lifestyle characteristics included smoking status (never/former/current), alcohol use (<1/1-2/>2 drinks per day), both assessed by standardised questionnaires, and physical activity, which was assessed by the International Physical Activity Questionnaire³⁸ and expressed in 1000 Metabolic Equivalent (MET)-minutes in the past week. MET reflects the ratio of the associated metabolic rate for specific activities divided by the resting metabolic rate multiplied by the minutes performed activity. CVD was considered to be present when participants self-reported a diagnosis of coronary heart disease, cardiac arrhythmia, angina, heart failure, or myocardial infarction, confirmed with the use of cardiovascular medication. Medication use of any kind within the past month was registered by observation of drug containers brought in, and coded according to the Anatomical Therapeutic Chemical Classification System (ATC).³⁹

Statistical analyses

Sample characteristics were summarized using means and standard deviations (SD) for quantitative variables and by percentages for categorical variables. Multivariate linear regression analyses were conducted to assess the association between each MASQ-D30 dimensions (i.e., PA, NA and SA) and the individual continuous MetSyn components and the total number of MetSyn components. Analyses for each dimension were performed separately. In order to normalize residuals, non-normally distributed dependent variables were naturally log-transformed. After running crude models, we adjusted for basic covariates

(i.e., age, sex and years of education) in model 1, and for additional lifestyle-related covariates (i.e., smoking status, alcohol use and physical activity) in model 2. Since sex differences in the association between anxiety, depression and the MetSyn have previously been observed,^{17,40} appropriate interaction terms with sex were explored. To evaluate the influence of prevalent CVD, participants diagnosed with CVD were excluded in a sensitivity analysis.

To evaluate whether the earlier described association between severity of depressive and anxious symptoms and MetSyn abnormalities were driven by symptom dimensions, additional regression analyses were performed. We analyzed the association of BAI and IDS-SR severity categories with the individual MetSyn components and the total number of components by performing linear regression analyses, adjusting for models 1 and 2 covariates and additionally adjusting for those symptom dimensions which showed to be significantly associated with the MetSyn components in the main analyses.

Multivariate logistic regression analyses were performed to assess the association between the standard deviations (SDs) of continuous scores of the three symptom dimensions and the MetSyn diagnosis. All assumptions for linearity were tested and fulfilled. All tests were two-tailed with $P < 0.05$ denoting statistical significance. Statistical analyses were done with SPSS 16.0 (SPSS Inc. Chicago, USA).

Results

General characteristics

Sample characteristics are shown in table 2. The mean age was 42.3 years (SD= 13.1), 33.1% were men, and mean number of years of education was 12.3 years (SD= 3.26). The criteria for the MetSyn were fulfilled by 20.1% ($n = 490$). The reported means and standard deviations for each dimension are calculated from the continuous values of all subjects included ($n=2433$) for that dimension.

Symptom dimensions and MetSyn components

Outcomes of the linear regression analyses between MASQ-D30 dimensions and MetSyn components are shown in Table 3. PA showed a significant association with every MetSyn component in the crude model. Adjustments in model 1 led to a decrease of the beta's (β) with more than 10% and to non-significant associations with WC, fasting glucose levels, and MBP. Analyses with the separate covariates of model 1 showed age to be the most important confounder. Associations of PA with triglycerides and HDL-cholesterol became statistically non-significant after adjustment for lifestyle factors (model 2). No significant associations were found for NA with any of the MetSyn components, in the unadjusted and fully adjusted models.

On the contrary, in the crude unadjusted model SA showed a significant association with all MetSyn components except for fasting glucose. The associations for SA remained significant in both adjusted models with regard to WC ($WC_{crude} : \beta = .061, P = .003$; $WC_{model2} :$

General characteristics	
Age	42.3 (13.1)
Sex (% men)	33.1
Years of education	12.3 (3.3)
Cardiovascular disease	5.8
Smoking status	
Never	29.3
Former	34.9
Current	35.8
Alcohol use (%)	
< 1 glasses/day	61.0
1–2 glasses/day	22.4
> 2 glasses/day	16.4
Physical activity (1000 MET minutes)	3.7 (3.1)
Metabolic syndrome components	
Waist circumference (cm)	88.7 (13.8)
HDL-cholesterol (mmol/L)	1.6 (0.4)
Triglycerides (mmol/L)	1.3 (0.8)
Glucose (mmol/L)	5.2 (0.9)
Systolic blood pressure (mmHg)	136.2 (19.7)
Diastolic blood pressure (mmHg)	81.5 (11.1)
Mean blood pressure (mmHg)	108.9 (14.7)
Number of metabolic syndrome components	1.45 (1.3)
Metabolic syndrome (%)	20.1
MASQ symptom dimensions	
Positive affect	33.4 (9.7)
Negative affect	20.0 (8.6)
Somatic arousal	15.7 (6.1)

Table 2. Sample characteristics in 2433 subjects.

Means and standard deviations (SD) are given for age, years of education, physical activity, number of metabolic syndrome components and the three symptom dimensions. Percentages are given for sex, smoking status, alcohol consumption, and presence of metabolic syndrome. HDL: High Density Lipoprotein; MET: Metabolic Equivalent.

$\beta = .046, P = .01$), triglycerides ($\text{Trig}_{\text{crude}}: \beta = .077, P < .001$; $\text{Trig}_{\text{model 2}}: \beta = .046, P = .02$) and MBP ($\text{MBP}_{\text{crude}}: \beta = .069, P < .001$; $\text{MBP}_{\text{model 2}}: \beta = .068, P < .001$). The significant crude association of SA with HDL-cholesterol weakened after adjustment in model 1, and further in model 2 to a non-significant level. Also the association of SA with the number of metabolic syndrome components (Nr.) remained highly statistically significant throughout all models ($\text{Nr.}_{\text{crude}}: \beta = .098, P < .001$; $\text{Nr.}_{\text{model 2}}: \beta = .062, P = .001$). The graded, positive association between SA and the number of MetSyn components, and SA and quartiles of the individual fully adjusted MetSyn components are shown in Figure 1. In sensitivity analyses in which 141 subjects with CVD were excluded, results did not change (data not shown). None of the interaction terms between dimensions with sex were statistically significant, which suggests that associations were largely similar for men and women.

To evaluate whether another measure for somatic symptoms would give comparable results, we repeated the linear regression model analyses with the validated BAI somatic subscale (36). These analyses confirmed an association for the somatic BAI subscale and a much less consistent association for the non-somatic BAI subscale. The associations with the BAI somatic scale score remained significant in the fully adjusted models for the number of MetSyn components (Nr. MetSyn: $\beta = .072$, $P < .001$), and all MetSyn components, except for HDL-cholesterol, which showed a trend towards significance with a $\beta = -.033$, $P = .08$ (WC: $\beta = .056$, $P < .001$; Trig: $\beta = .083$, $P < .001$; Gluc: $\beta = .038$, $P = .04$; MBP: $\beta = .046$, $P = .01$). There was a strong intercorrelation between the somatic symptom dimension of the MASQ (SA) and the subscale of the BAI ($r_{\text{sBAI}} = .73$, $p = P < .001$). We did not analyse associations with subscales of the Inventory of Depressive Symptoms self-report (IDS-SR) because earlier work by Wardenaar et al.⁴¹ did identify three subscales but none of these was a clear somatic subscale (in factor analyses the –rather restricted- somatic items were attributed to all three subscales). So, no valid somatic IDS subscale exists. Therefore it is not appropriate to use a subscale in a comparative analysis. To explore whether results would also be consistent for the non-somatic symptom subscale, we also conducted linear regression analyses with the non-somatic BAI subscale (Beck Anxiety Inventory: subjective scale score). We expected that associations for the subjective BAI subscale would be similar to those for the PA and NA dimensions of the MASQ-30 which was indeed confirmed. None of the associations with the BAI subjective scale score were statistically significant in the fully adjusted models, with exception of the number of MetSyn components ($\beta = .041$, $P = .02$).

Regression analyses performed to investigate whether previously found positive associations between MetSyn abnormalities and symptom severity were driven by symptom dimensions, in particular the SA dimension, showed the following: initial significant outcomes (in which the number of MetSyn components was the dependent variable and BAI and IDS-SR severity categories were the independent variables) lost statistical significance after adjustment with the SA dimension. This means that the earlier described associations between the high severe groups according to the BAI and IDS-SR with the MetSyn were largely attributable to a high SA score.

Symptom dimensions and the cluster of the MetSyn

Logistic regression analyses of the symptom dimension with the MetSyn, showed a small but significant crude relationship between PA and the MetSyn. NA was not significantly associated with the MetSyn. The initial significant crude relationship between SA and the MetSyn remained statistically significant throughout multivariable adjustment (OR per SD increase = 1.15 (95%CI 1.04-1.28; $P < .008$; Table 4). Analyses, in which the associations of BAI or IDS severity categories with the MetSyn were adjusted for SA, showed that the severity category indicator lost statistical significance after adjustment.

	Waist circumference		Triglycerides		HDL-cholesterol		Glucose		Blood pressure		Nr. of metabolic syndrome components	
	β	P value	β	P value	β	P value	β	P value	β	P value	β	P value
Negative affect												
Crude	.070	.001	.097	< .001	-.063	< .01	.079	< .001	.076	< .001	.107	< .001
Model 1	-.001	.94	.044	.02	-.039	.04	.027	.15	.008	.64	.036	.05
Model 2	-.009	.60	.021	.29	-.012	.52	.026	.17	.009	.63	.019	.29
Positive affect												
Crude	-.002	.93	.031	.12	-.036	.08	.008	.68	-.028	.17	.018	.37
Model 1	.016	.34	.042	.03	-.017	.36	.036	.05	-.001	.94	.033	.07
Model 2	.011	.51	.022	.25	.001	.08	.037	.05	-.002	.90	.020	.27
Somatic arousal												
Crude	.061	< .01	.077	< .001	-.056	.01	.025	.22	.069	< .001	.098	< .001
Model 1	.050	.01	.064	.001	-.045	.02	.023	.21	.062	< .001	.074	< .001
Model 2	.046	.01	.046	.02	-.018	.32	.023	.22	.068	< .001	.062	.001

Table 3. Linear regression for association between MASQ dimensions and metabolic syndrome components in 2433 subjects. β , standardized beta by linear regression analyses. Abbreviations: HDL, high density lipoprotein. Model 1: adjusted for age, sex and years of education (sociodemographic factors). Model 2: additionally adjusted for smoking status, alcohol use and physical activity (life style factors).

Discussion

The main finding of this study is that only the somatic arousal (SA) symptom dimension is strongly and independently associated with most of the MetSyn components (especially waist circumference, triglycerides and mean blood pressure), and shows a graded association with the number of MetSyn components. Using a dimensional approach, somatic arousal was thus associated with an increased metabolic risk. No independent associations between MetSyn with negative affect (NA) and positive affect (PA) were observed. These results are supported by our finding that also the somatic scale of the BAI is associated with the MetSyn components, while the non-somatic scales are not.

	OR	95% CI	P value
Positive affect			
Crude	1.16	1.05-1.28	< .01
Model 1	1.02	0.92-1.14	.67
Model 2	0.99	0.88-1.10	.99
Negative affect			
Crude	1.01	0.92-1.12	.78
Model 1	1.01	0.99-1.02	.28
Model 2	1.04	0.93-1.16	.51
Somatic arousal			
Crude	1.19	1.08-1.31	< .001
Model 1	1.18	1.06-1.30	< .01
Model 2	1.15	1.04-1.28	< .01

Table 4. Logistic regression for the association between standard deviations (SDs) of continuous scores on MASQ dimensions and the odds of metabolic syndrome in 2433 subjects.

Abbreviations: OR, odds ratio per SD increase by logistic regression analysis; CI, confidence interval; MASQ, Mood and Anxiety Symptom Questionnaire. Model 1: adjusted for age, sex, years of education. Model 2: additionally adjusted for lifestyle factors: smoking status, alcohol use and physical activity.

Approaching depression and anxiety dimensionally, the a-specific NA dimension and the depression specific PA dimension did not show any association with the MetSyn. We only found a strong and consistent relationship between the somatic arousal dimension and multiple MetSyn components. This is in line with previous research on symptom dimensions of especially depression in relation to somatic outcomes, in which the somatic/affective sub-dimension, rather than other important dimensions (e.g., cognitive/affective and appetitive) was most strongly associated with cardiovascular risk and outcome.^{42,43} It seems we are looking at a specific sub-dimension: the 'somatic depression/anxiety' sub-dimension. On the one hand, this subtype could be reflective of underlying dysregulated homeostasis

mechanisms due to anxious or depressed mood states such as inflammation,⁴⁴ impaired hypothalamus-pituitary-adrenal axis (HPA-axis) function^{45;46} or a higher sympathetic and lower parasympathetic autonomic tone.⁴⁷ Elevated inflammatory markers levels could induce a depressive episode;⁴⁸ altered lipid patterns caused by high levels of cortisol^{4;49} could lead to other lipid related symptoms (overweight, abdominal obesity and hypertriglyceridemia);^{4;22;50} and activation of sympathetic nervous system leads to increased blood pressure⁵¹ and thus to hypertension.^{4;52} This network of pathways can thus result in an increased metabolic or cardiovascular risk and cardiovascular disease. On the other hand, also the reverse mechanism could be active: ongoing metabolic dysregulations could be causing (especially somatic arousal) symptoms of depression and anxiety.⁵³⁻⁵⁷ Regardless of the underlying mechanisms and the direction of causality, the dose-response gradient between the number of MetSyn components and levels of SA indicates that when more somatic arousal symptoms are present, also more MetSyn abnormalities are present. Apart from biological mechanisms, other processes may be involved during a depressive episode as a consequence of anhedonia, such as altered lifestyle patterns (poor diet and decreased physical activity)^{58;59} which might induce metabolic changes and cardiovascular risk factors.

Previous research based on NESDA data⁸ showed that the prevalence rates of the MetSyn were increased in those with the highest levels of depressive symptoms based on the Beck Anxiety Inventory (BAI) and the Inventory of Depressive Symptoms self-report (IDS/SR). After adjustment for the MASQ SA dimension, the earlier described associations lost statistical significance. These results indicate that the earlier described association between MetSyn and the most severe depression and anxiety symptom scales can be explained by the fact that these persons had high scores on the somatic arousal (SA) dimension.

In terms of metabolic risk evaluation and detection, a dimensional approach has more differentiating capacities compared to the widely used diagnostic *DSM-IV* categories. The somatic symptom dimension could therefore be the key feature in the association between depression/anxiety and somatic outcomes.

Using a dimensional approach, the level of a symptom dimension varies differentially between diagnostic groups (e.g., singular depression, singular anxiety or comorbid state). At the same time, all symptom dimensions can be present at a significant level within every diagnostic group. This means that the clinical presentation of a subject is dependent on the symptom dimension(s) with the highest scores. Our results demonstrate that the SA dimension is associated with several MetSyn components. The fact that SA levels are not equally high for every depressed and/or anxious subject, might explain the inconsistent findings in literature on the association with the MetSyn.

Our study has several strengths. This is, to our knowledge, the first study describing the relationship between depression and anxiety dimensions in relation to the MetSyn.

Not only we approached the MetSyn and its components as continua, in line with the idea that that MetSyn components have a natural continuous distribution,⁶⁰ but also distinguished




Figure 1. Adjusted (geometric) means across quartiles of somatic arousal on the MASQ-D30, for the individual MetSyn components and the total number of MetSyn components. Data are adjusted for age, sex, educational level, alcohol consumption, smoking status and physical activity. Error bars indicate 95% confidence intervals of the mean, and regression lines are shown. $N_{\text{quartile 1}}=744$; $N_{\text{quartile 2}}=436$; $N_{\text{quartile 3}}=652$; $N_{\text{quartile 4}}=601$.

depression and anxiety symptom dimensions.⁶⁰ Because we chose this approach, we were able to show a dose-response gradient with somatic arousal levels. Further, the results are based on a large sample, making results reliable. Finally, in the analyses we adjusted for a substantial number of covariates, minimizing the chance that the findings can be explained by confounding. Despite the strengths, this study presents some limitations. First, the tripartite model is a rather simple dimensional model. Probably, there are more relevant sub-dimensions present.⁶¹ Second, the sample includes both healthy controls and subjects with (remitted) psychopathology, recruited from community as well as mental health care settings. As inpatients were excluded, our results cannot be generalized to this group. Third, the concept of the MetSyn has been criticized,^{15,16} and our findings support the idea that it may be worthwhile to study (the number of) individual metabolic components in addition to a dichotomous MetSyn variable. Finally, due to the cross-sectional design, our results cannot be used to make any causal inferences. Prospective studies, especially across more heterogeneous populations, would help to understand the direction of the potential causal relationship.

In this sample, in which previously the association between a categorical diagnosis on the one hand, and the MetSyn components on the other hand was found only for the most severe depressive symptoms we demonstrate a strong association between the SA symptom dimension and the metabolic syndrome and its individual components, especially waist circumference, triglycerides and blood pressure, and the number of MetSyn components. Not every depressed subject is at increased metabolic risk. But our findings suggest that those with an elevated somatic arousal level are. Those with elevated non-somatic dimensions scores (i.e., positive affect and negative affect) did not show an increased metabolic risk. This indicates the additional value of a dimensional approach in terms of metabolic risk evaluation. In addition, we found that the association between depression severity (BAI severity categories) and the MetSyn is in part driven by the SA dimension. Although our results need to be replicated, the discriminating ability of a dimensional approach could facilitate the identification of those with a higher metabolic risk within a clinical population with apparently the same diagnoses.

References

1. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. *Psychosom Med* 2004;66:802-813.
2. Penninx BW, Beekman AT, Honig A et al. Depression and cardiac mortality: results from a community-based longitudinal study. *Arch Gen Psychiatry* 2001;58:221-227.
3. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735-2752.
4. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? *Obes Rev* 2001;2:73-86.
5. Heiskanen TH, Niskanen LK, Hintikka JJ et al. Metabolic syndrome and depression: a cross-sectional analysis. *J Clin Psychiatry* 2006;67:1422-1427.
6. Carroll D, Phillips AC, Thomas GN, Gale CR, Deary I, Batty GD. Generalized anxiety disorder is associated with metabolic syndrome in the Vietnam experience study. *Biol Psychiatry* 2009;66:91-93.
7. Skilton MR, Moulin P, Terra JL, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. *Biol Psychiatry* 2007;62:1251-1257.
8. van Reedt Dortland AK, Giltay EJ, van VT, Zitman FG, Penninx BW. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. *Acta Psychiatr Scand* 2010;122:30-39.
9. Ierodiakonou CS, Iacovides A. Somatic manifestations of depressive patients in different psychiatric settings. *Psychopathology* 1987;20:136-143.
10. Almeida OP, Calver J, Jamrozik K, Hankey GJ, Flicker L. Obesity and metabolic syndrome increase the risk of incident depression in older men: the health in men study. *Am J Geriatr Psychiatry* 2009;17:889-898.
11. Franko DL, Striegel-Moore RH, Thompson D, Schreiber GB, Daniels SR. Does adolescent depression predict obesity in black and white young adult women? *Psychol Med* 2005;35:1505-1513.
12. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Vanhala M. Depressive symptoms and 10-year risk for cardiovascular morbidity and mortality. *World J Biol Psychiatry* 2010;11:834-839.
13. Goldbacher EM, Bromberger J, Matthews KA. Lifetime history of major depression predicts the development of the metabolic syndrome in middle-aged women. *Psychosom Med* 2009;71:266-272.
14. Goldberg D. A dimensional model for common mental disorders. *Br J Psychiatry Suppl* 1996;44-49.
15. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2005;28:2289-2304.
16. Reaven GM. The metabolic syndrome: requiescat in pace. *Clin Chem* 2005;51:931-938.
17. Toker S, Shirom A, Melamed S. Depression and the metabolic syndrome: gender-dependent associations. *Depress Anxiety* 2008;25:661-669.

18. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. *Circulation* 1996;93:1976-1980.
19. Frasure-Smith N, Lesperance F. Reflections on depression as a cardiac risk factor. *Psychosom Med* 2005;67 Suppl 1:S19-S25.
20. Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. *J Abnorm Psychol* 2001;110:585-599.
21. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry* 1994;51:8-19.
22. Veen G, van Vliet IM, Derijk RH, Giltay EJ, van PJ, Zitman FG. Basal cortisol levels in relation to dimensions and DSM-IV categories of depression and anxiety. *Psychiatry Res* 2011;185:121-128.
23. MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization of quantitative variables. *Psychol Methods* 2002;7:19-40.
24. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. *J Abnorm Psychol* 1991;100:316-336.
25. de Beurs E, Hollander-Gijsman ME, Helmich S, Zitman FG. The tripartite model for assessing symptoms of anxiety and depression: Psychometrics of the Dutch version of the mood and anxiety symptoms questionnaire. *Behaviour Research and Therapy* 2007;45:1609-1617.
26. Watson D, Weber K, Assenheimer JS, Clark LA, Strauss ME, McCormick RA. Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales. *J Abnorm Psychol* 1995;104:3-14.
27. Penninx BW, Beekman AT, Smit JH et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *Int J Methods Psychiatr Res* 2008;17:121-140.
28. Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME, McCormick RA. Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. *J Abnorm Psychol* 1995;104:15-25.
29. Chorpita BF, Daleiden EL. Tripartite dimensions of emotion in a child clinical sample: measurement strategies and implications for clinical utility. *J Consult Clin Psychol* 2002;70:1150-1160.
30. Wardenaar KJ, van Veen T, Giltay EJ, de Beurs E, Penninx BW, Zitman FG. Development and validation of a 30-item short adaptation of the Mood and Anxiety Symptoms Questionnaire (MASQ). *Psychiatry Res* 2010.
31. Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADVICOR Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). *Am J Cardiol* 2003;91:667-672.
32. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). *Am J Cardiol* 2005;95:462-468.
33. Vogelzangs N, Suthers K, Ferrucci L et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. *Psychoneuroendocrinology* 2007;32:151-159.
34. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. *JAMA* 1991;265:3255-3264.

35. Tannen RL, Weiner MG, Marcus SM. Simulation of the Syst-Eur randomized control trial using a primary care electronic medical record was feasible. *J Clin Epidemiol* 2006;59:254-264.
36. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol* 1988;56:893-897.
37. IDS guide, 2008. <http://www.ids-qids.org/index2.html#table3>.
38. Booth M. Assessment of physical activity: an international perspective. *Res Q Exerc Sport* 2000;71:S114-S120.
39. WHO, 2009. Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification. www.whocc.no/atc_ddd_index/.
40. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. *Psychosom Med* 2004;66:316-322.
41. Wardenaar KJ, van Veen T, Giltay EJ, Hollander-Gijsman M, Penninx BW, Zitman FG. The structure and dimensionality of the Inventory of Depressive Symptomatology Self Report (IDS-SR) in patients with depressive disorders and healthy controls. *J Affect Disord* 2010.
42. Bosch NM, Riese H, Dietrich A, Ormel J, Verhulst FC, Oldehinkel AJ. Preadolescents' somatic and cognitive-affective depressive symptoms are differentially related to cardiac autonomic function and cortisol: the TRAILS study. *Psychosom Med* 2009;71:944-950.
43. de Jonge P, Ormel J, van den Brink RH et al. Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. *Am J Psychiatry* 2006;163:138-144.
44. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom Med* 2009;71:171-186.
45. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? *Biol Psychiatry* 2004;55:1-9.
46. Vreeburg SA, Hoogendijk WJ, van Pelt J et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. *Arch Gen Psychiatry* 2009;66:617-626.
47. Licht CM, Vreeburg SA, Reedt Dortland AK et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. *J Clin Endocrinol Metab* 2010;95:2458-2466.
48. Bremner MA, Beekman AT, Deeg DJ et al. Inflammatory markers in late-life depression: results from a population-based study. *J Affect Disord* 2008;106:249-255.
49. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. *Int J Obes Relat Metab Disord* 2000;24 Suppl 2:S50-S55.
50. Vogelzangs N, Beekman AT, Dik MG et al. Late-life depression, cortisol, and the metabolic syndrome. *Am J Geriatr Psychiatry* 2009;17:716-721.
51. Shibao C, Gamboa A, Diedrich A et al. Autonomic contribution to blood pressure and metabolism in obesity. *Hypertension* 2007;49:27-33.
52. Lambert E, Dawood T, Straznicky N et al. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. *J Hypertens* 2010;28:543-550.

53. Ajilore O, Haroon E, Kumaran S et al. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. *Neuropsychopharmacology* 2007;32:1224-1231.
54. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. 'Vascular depression' hypothesis. *Arch Gen Psychiatry* 1997;54:915-922.
55. Huber JD. Diabetes, cognitive function, and the blood-brain barrier. *Curr Pharm Des* 2008;14:1594-1600.
56. Mast BT, Miles T, Penninx BW et al. Vascular disease and future risk of depressive symptomatology in older adults: findings from the Health, Aging, and Body Composition study. *Biol Psychiatry* 2008;64:320-326.
57. Steffens DC, Krishnan KR, Crump C, Burke GL. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study. *Stroke* 2002;33:1636-1644.
58. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. *Circulation* 2005;112:505-512.
59. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. *JAMA* 2002;288:2569-2578.
60. Ingram DG. Is the metabolic syndrome a discrete diagnostic category or the end of a continuum? Taxometric evidence for dimensionality in the National Health and Nutrition Examination Survey 1999-2004. *Ann Epidemiol* 2009;19:143-147.
61. Hollander-Gijsman ME, de Beurs E, van der Wee NJ, van Rood YR, Zitman FG. Distinguishing between depression and anxiety: A proposal for an extension of the tripartite model. *Eur Psychiatry* 2010;25:197-205.

